Abstract: An objective of the present invention is to provide a packaging cell for preparing a retrovirus having a high viral titer. The cell producing a recombinant retrovirus is constructed by introducing, the Polyoma virus early region gene together with a recombinant plasmid or a recombinant retrovirus free from any replication origin derived from Polyoma virus into a packaging cell for preparing a recombinant retrovirus.

Abstract: A method of inhibiting the growth of a tumor cell in a mammal by administering to the mammal an autoantibody, e.g, an antinuclear autoantibody from an aged mammal, that binds to either one or both of a surface of a tumor cell and a protein released from a dead tumor cell. Also disclosed are natural and monoclonal antinuclear autoantibodies from aged mammals and a hybridoma cell line producing a monoclonal antinuclear autoantibody.

Abstract: The invention relates to an anti-immunodeficiency virus antibody which binds to a cellular protein and diagnostic and therapuetic methods of using the same.

Abstract: Disclosed is a method for quantitatively determining an antibody, contained in a biological sample, having the ability to inhibit the activity of a reverse transcriptase derived from an HIV, comprising: reacting a hybridization product, immobilized on a solid phase, of a primer consisting essentially of oligodeoxythymine nucleotide and an RNA template consisting essentially of adenine ribopolynucleotide with a reverse transcriptase derived from HIV, to thereby bind the reverse transcriptase to the hybridization product; conducting a synthesis of a DNA complementary to the RNA template from a deoxymononucleotide triphosphate in the presence of the reverse transcriptase activity-inhibiting antibody; and measuring the amount of the synthesized DNA and quantitatively determining the above-mentioned antibody, based on the measured amount of the synthesized DNA.

Abstract: The invention relates to methods of agglutinating or capturing cells comprising providing a mixture comprising a population of cells and a population of bacteriophage expressing a first antibody on the surface of the bacteriophage, the first antibody being specific for an antigen-bearing moiety expressed by at least a portion of the cells in the cell population, wherein the first antibody binds to the portion of the cells causing the bacteriophage to also bind to the portion of the cells, adding to the mixture a second antibody specific for the bacteriophage, wherein binding of the second antibody to bacteriophage bound to the portion of the cells causes the portion of the cells to agglutinate or be captured.

Abstract: An artificial peptide having an amino acid sequence which corresponds to a naturally occurring amino acid sequence of a HIV comprising an epitope and which further has two cysteine residues located on each side of said epitope, and further having a sulphur bridge between said two cysteine residues, which has been formed by a chemical oxidation step, is described.Furthermore, an artificial antigen which reacts with antibodies induced by a HIV is described. Said antigen mainly consists of an artificial peptide according to the invention.Additionally, a method of detecting antibodies induced by a HIV in a sample of body fluid, wherein said sample is subjected to an immunoassay, especially ELISA, and wherein an artificial antigen according to the invention is used as a diagnostic antigen, is described. A diagnostic immunoassay kit for said method is also described.Finally, a vaccine composition comprising, as an immunizing component, at least one antigen according to the invention, is described.

Abstract: A polypeptide for use in a vaccine against Bordetella pertussis, B. parapertussis or B. bronchiseptica contains an epitope selected from (a) the amino acid sequence coded for by nucleotides 1885 to 1902 of the P.69 gene of B. pertussis CN2992; (b) the corresponding amino acid sequence of another strain of B. pertussis or of a strain of B.parapertussis or B. bronchiseptica; and (c) a modified version of sequence (a) or (b) which has substantially the same antigenicity. The polypeptide is no more than 50 amino acid residues long or is a chimaeric protein composed of a carrier protein sequence and a sequence of no more than 50 amino acid residues which contains the required epitope.

Abstract: An antibody or antibody fragment with a binding affinity for the CD3 antigen, having a human constant region, and human or rat variable framework region, a heavy chain with CDRs having the amino acid sequences:(a) Ser-Phe-Pro-Met-Ala (SEQ ID NO:1),(b) Thr-Ile-Ser-The-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly (SEQ ID NO:2),(c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr (SEQ ID NO:3),and light chain with CDRs having the amino acid sequences:(d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Tyr-Val-His (SEQ ID NO:4),(e) Asp-Asp-Asp-Lys-Arg-Pro-Asp (SEQ ID NO:5),(f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val (SEQ ID NO:6),in which the heavy chain CDRs are arranged in the order (a), (b), (c) in the leader.fwdarw.constant region direction and the light chain CDRs are arranged in the order (d), (e), (f) in the leader.fwdarw.constant region direction.

Abstract: This invention is directed to monoclonal antibodies produced by using CD4-expressing T lymphocytes, such as peripheral blood mononuclear T cells, thymocytes, splenocytes and leukemia or lymphoma derived T cell line cells such as HPB-ALL or SUP-T as the immunogen in accordance with the protocols and screening procedures described. The monoclonal antibodies of the present invention are characterized by their ability to neutralize in vitro and in vivo primary isolates of Human Immunodeficiency Virus (HIV) and related immunodeficiency viruses. The antibodies are directed against a host cell antigen complex comprising CD4 protein in association with domains from chemokine receptors and have broad neutralizing activities against primary isolates from all clades of HIV type 1 (HIV-1) and primary isolates of HIV type 2 (HIV-2) and Simian Immunodeficiency Virus (SIV).

Abstract: A method for treating human T cell lymphotrophic virus type 1 infection using an isozyme selective PKC inhibitor, particularly using the isozyme selective PKC inhibitor, (S)-3,4-?N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione hydrochloride salt.

Abstract: The present invention provides a novel dipeptide compound or pharmaceutically acceptable salt thereof which exhibits an excellent HIV protease inhibitory activity and an excellent bioavailability from digestive tracts, and an anti-AIDS agent comprising said dipeptide compound as an effective ingredient. ##STR1## (wherein R.sub.1 represents 5-membered or 6-membered monocyclic hydrocarbon group or heterocyclic group wherein more than one carbon atom of said monocyclic hydrocarbon group is substituted with hetero atom. X represents methylene group (--CH.sub.2 --), chloromethylene group(--CH(Cl)--), oxygen atom sulfur atom or sulfonyl group (--SO.sub.2 --). R.sub.21 and R.sub.22 each represents hydrogen atom or aliphatic hydrocarbon group having 1-6 carbons. R.sub.3 represents aliphatic hydrocarbon group or monovalent group derived from aromatic monocyclic hydrocarbon having 1-6 carbons.

Abstract: One sigmoid calibration curve is split into three parts of low concentration region represented by a high degree function, intermediate concentration region represented by an exponential function and high concentration region represented by a high degree function according to the present invention. The boundary condition of the adjacent two functions is set so that the two functions have an equal slope at the boundary point; thereby, regression functions of the calibration curves in respective regions are found. The number of standard samples for finding a calibration curve can be reduced while the calibration curve found is of high accuracy.

Abstract: The present invention provides a novel dipeptide compound or pharmaceutically acceptable salt thereof which exhibits an excellent HIV protease inhibitory activity and an excellent bioavailability from digestive tracts, and an anti-AIDS agent comprising said dipeptide compound as an effective ingredient.General formula (I): ##STR1## (wherein R.sub.1 represents 5-membered or 6-membered monocyclic hydrocarbon group or heterocyclic group wherein more than one carbon atom of said monocyclic hydrocarbon group is substituted with hetero atom. X represents methylene group (--CH.sub.2 --), chloromethylene group(--CH(Cl)--), oxygen atom sulfur atom or sulfonyl group (--SO.sub.2 --). R.sub.21 and R.sub.22 each represents hydrogen atom or aliphatic hydrocarbon group having 1-6 carbons. R.sub.3 represents aliphatic hydrocarbon group or monovalent group derived from aromatic monocyclic hydrocarbon having 1-6 carbons.

Abstract: Heterohybridomas producing human monoclonal antibodies against a neutralizing epitope of HIV-1 are prepared by transforming peripheral blood lymphocytes by Epstein-Barr virus, selecting cells producing an antibody to a synthetic peptide representing part of the neutralizing epitope, and fusing them with a heteromyeloma cell. A method for producing a human monoclonal antibody specific for a neutralizing HIV-1 epitope from the heterohybridoma is disclosed. Also provided are human neutralizing monoclonal antibodies specific for particular peptide epitopes of the V3 loop of the gp120 glycoprotein of HIV, in particular a broadly reactive antibody specific for diverse HIV-1 strains, preferably recognizing an epitope comprising an amino acid sequence GPXR or GRAF.

Abstract: This invention is directed to monoclonal antibodies produced by using CD4-expressing T lymphocytes, such as peripheral blood mononuclear T cells, thymocytes, splenocytes and leukemia or lymphoma derived T cell line cells such as HPB-ALL or SUP-T as the immunogen in accordance with the protocols and screening procedures described. The monoclonal antibodies of the present invention are characterized by their ability to neutralize in vitro and in vivo primary isolates of Human Immunodeficiency Virus (HIV) and related immunodeficiency viruses. The antibodies are directed against a host cell antigen complex comprising CD4 protein in association with domains from chemokine receptors and have broad neutralizing activities against primary isolates from all clades of HIV type 1 (HIV-1) and primary isolates of HIV type 2 (HIV-2) and Simian Immunodeficiency Virus (SIV).

Abstract: Isolated peptides and polypeptides exhibiting the antigenicity of the 70 kD mitochondrial autoantigen of primary biliary cirrhosis are provided. The peptides, polypeptides and antigenic fragments thereof are useful in the diagnosis and treatment of primary biliary cirrhosis.

Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.

Abstract: The subject invention pertains to methods of treating immunocompromised patients, such as individuals infected with HIV, that exhibit elevated levels of IgA relative to IgG. The use of IgA-binding compositions immobilized onto a support matrix to extracorporeally remove IgA molecules from a sample or biological fluid for therapeutic purposes is provided by the present invention. The subject invention further pertains to novel polypeptides which bind in a specific manner to human IgA. The polypeptides of the present invention comprise an IgA-binding region from an IgA-binding protein of Group B streptococcal bacteria.

Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8.sup.+ suppressor molecule, that is produced by the CD8.sup.+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of clonal CD8.sup.+ cells lines that produce the antiviral activity and the development of an assay system for detection of the antiviral activity. The clonal cell lines and the assay system, described herein, may be utilized to purify, characterize and clone the CD8.sup.+ suppressor molecule. The CD8.sup.+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.

Abstract: The present invention is directed to a recombinant human monoclonal antibody which binds to a discontinuous epitope on the HIV gp120 envelope glycoprotien, blocks the binding of gp120 to the CD4 receptor, and neutralizes a broad range of HIV isolates. The present invention also provides the primary nucleotide and deduced amino acid sequences of the rearranged heavy and light chains of the recombinant monoclonal antibody of the present invention, and a method of screening for antibodies which block binding of envelope glycoprotein to the CD4 receptor.